| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Clopamide targets the sodium-coupled chloride cotransporter SLC12A3 in the distal convoluted tubules of the kidneys. It acts as an inhibitor, blocking the reabsorption of sodium and chloride ions. This promotes diuresis and reduces blood volume, leading to antihypertensive effects.
|
|---|---|
| ln Vitro |
Renal tubular cells actively secrete clopamide, which has a true tubular excretion fraction (TTEF) of 10% [3].
In vitro, Clopamide is a thiazide-like diuretic that inhibits the sodium-coupled chloride cotransporter. Its activity can be measured in cell-based assays using cells expressing SLC12A3. The inhibition of ion transport is measured using electrophysiological or flux assays. |
| ln Vivo |
In conscious dogs, cyclosporine-A (1–10 μg/min) is concurrently infused locally and clopamide (0.5 mg/kg) is administered orally to reduce the venoconstrictive response to bradykinin [4].
In vivo, Clopamide is an orally active diuretic with antihypertensive effects. It is used to treat hypertension and edema. It was first synthesized in the 1960s. It has a distinct chemical structure but similar pharmacological effects to classical thiazides. |
| Enzyme Assay |
Clopamide is evaluated in cell-free assays to measure its inhibition of the sodium-coupled chloride cotransporter. However, specific enzymatic assays are not well-documented. Its activity is primarily assessed in cell-based and in vivo systems.
|
| Cell Assay |
Clopamide is assessed in cell-based assays using cells expressing SLC12A3. Cells are treated with Clopamide, and the inhibition of sodium and chloride uptake is measured. Its effects on ion transport and cell function are evaluated.
|
| Animal Protocol |
Clopamide is administered orally in animal models and in clinical settings to treat hypertension and edema. It promotes diuresis and reduces blood volume. Efficacy is assessed by measuring blood pressure and urine output.
|
| ADME/Pharmacokinetics |
Clopamide has a molecular weight of 345.84 and a molecular formula of C14H20ClN3O3S. It has a CAS number of 636-54-4. The compound is a solid. It is soluble in ethanol and partly miscible in water. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Clopamide beyond its known use as a diuretic. It can cause electrolyte imbalances. The compound is a therapeutic agent and is available by prescription only.
|
| References | |
| Additional Infomation |
4-Chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfonamide is a sulfonamide drug. Clopyramide is an oral diuretic with antihypertensive effects. Similar to thiazide diuretics, it has an aromatic sulfonamide group but lacks a bicyclic structure. Clopyramide is a piperidine and sulfonamide-based diuretic with thiazide-like activity. The mechanism of action of clopyramide appears to be similar to that of thiazide diuretics, and its potency is similar to chlorothiazide and hydrochlorothiazide. It is a sulfonamide-piperidine drug. It is considered a thiazide-like diuretic.
Clopamide is also known as Brinaldix. It is a thiazide-like diuretic. The compound is a therapeutic agent. |
| Molecular Formula |
C14H20CLN3O3S
|
|---|---|
| Molecular Weight |
345.84
|
| Exact Mass |
345.091
|
| CAS # |
636-54-4
|
| PubChem CID |
2804
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
244-246ºC
|
| Index of Refraction |
1.613
|
| LogP |
1.59
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
498
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LBXHRAWDUMTPSE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H20ClN3O3S/c1-9-4-3-5-10(2)18(9)17-14(19)11-6-7-12(15)13(8-11)22(16,20)21/h6-10H,3-5H2,1-2H3,(H,17,19)(H2,16,20,21)
|
| Chemical Name |
4-chloro-N-(2,6-dimethylpiperidin-1-yl)-3-sulfamoylbenzamide
|
| Synonyms |
Brinaldix; Aquex; Clopamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~722.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8915 mL | 14.4576 mL | 28.9151 mL | |
| 5 mM | 0.5783 mL | 2.8915 mL | 5.7830 mL | |
| 10 mM | 0.2892 mL | 1.4458 mL | 2.8915 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
